131I-rituximab for Relapsed or Refractory Follicular or Mantle Cell Lymphoma

Sponsor
Korea Cancer Center Hospital
Study ID
NCT01678417
Phase
PHASE2
Status
Unknown

Conditions

  • Relapsed or Refractory Follicular Lymphoma or Mantle Cell Lymphoma

Eligibility Criteria

Sex
ALL
Age
20 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

Follicular lymphoma (FL) and mantle cell lymphoma (MCL) are rare lymphomas which consist of less than 5% of non-Hodgkin lymphoma in Korea. Although FL with histologic grade 1 or 2 has relatively good prognosis, continual treatment is needed due to frequent relapse. FL with histologic grade 3 has poor prognosis similar to that of diffuse large B cell lymphoma. Meanwhile, the response rate to systemic chemotherapy in MCL is low, so the treatment of relapsed MCL is challenging. So we investigate the efficacy of radioimmunotherapy using 131I-rituximab in refractory or relapsed patients with FL or MCL

Key Dates

Start date
Jun 30, 2012
Status verified
Aug 2012
Primary completion
Jun 30, 2017
Completion
Jun 30, 2017

Study Design

Enrollment
29 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: 131I-rituximab
    131I-rituximab treatment interval at least 4 weeks up to maximum 6 cycles

Primary Outcome Measure

Overall response rate [ Time Frame: up to 5 years ]

Central Contacts